BetsyLongeneckerMD

Family Medicine • Grand Junction, CO

Physician

Join to view full profile

Are you Dr. Longenecker?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 35 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
2698 Patterson Rd
Grand Junction, CO 81506
Phone+1 970-298-2800

Fax+1 970-298-6291
Is this information wrong?

Summary

Dr. Betsy Longenecker, MD is a family physician in Grand Junction, Colorado. She is currently licensed to practice medicine in Colorado and Arizona. She is affiliated with SCL Health - St. Mary's Hospital and Medical Center.

Education & Training

University of Arizona College of Medicine-PhoenixResidency, Family Medicine, 1982 - 1985
University of Kansas School of MedicineClass of 1982

Certifications & Licensure

AZ State Medical License 1983 - Present
CO State Medical License 1987 - 2025

Publications & Presentations

PubMed

Glycosylations versus conformational preferences of cancer associated mucin core.
Schuman, J., Qiu, D., Koganty, R. R., Longenecker, B. M., Campbell, A. P.> ;Glycoconj J. 2000 Dec
Association of MUC-1 and SPGL-1 with low-density microdomain in T-lymphocytes: a preliminary note.
Handa, K., Jacobs, F., Longenecker, B. M., Hakomori, S. I.> ;Biochem Biophys Res Commun. 2001 Jul 20
Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.
Moase, E. H., Qi, W., Ishida, T., Gabos, Z., Longenecker, B. M., Zimmermann, G. L., Ding, L., Krantz, M., Allen, T. M.> ;Biochim Biophys Acta. 2001 Feb 9
A low-level expression of human MUC1 mucin enhances lethality of murine tumor cells.
Zimmermann, G. L., Krantz, M. J., Kane, K. P., Longenecker, B. M.> ;Cancer Immunol Immunother. 2000 Aug
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg, L. A., Oparin, D. V., Gooley, T., Lilleby, K., Bensinger, W., Reddish, M. A., MacLean, G. D., Longenecker, B. M., Sandmaier, B. M.> ;Bone Marrow Transplant. 2000 Jun
Anti-T antibodies and peanut-agglutinin-binding glycoproteins in sera of patients with gastric cancer.
Hwang, I. R., Nahm, D. H., Cho, S. N., Longenecker, B. M., Rao Koganty, R., Park, I. S.> ;J Cancer Res Clin Oncol. 1999 Oct
Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers a...
Ragupathi, G., Howard, L., Cappello, S., Koganty, R. R., Qiu, D., Longenecker, B. M., Reddish, M. A., Lloyd, K. O., Livingston, P. O.> ;Cancer Immunol Immunother. 1999 Apr
Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Th...
Sandmaier, B. M., Oparin, D. V., Holmberg, L. A., Reddish, M. A., MacLean, G. D., Longenecker, B. M.> ;J Immunother. 1999 Jan
Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes.
Agrawal, B., Krantz, M. J., Reddish, M. A., Longenecker, B. M.> ;Int Immunol. 1998 Dec
MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats.
Kam, J. L., Regimbald, L. H., Hilgers, J. H., Hoffman, P., Krantz, M. J., Longenecker, B. M., Hugh, J. C.> ;Cancer Res. 1998 Dec 1
The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences.
Agrawal, B., Reddish, M. A., Christian, B., VanHeele, A., Tang, L., Koganty, R. R., Longenecker, B. M.> ;Cancer Res. 1998 Nov 15
The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy.
Agrawal, B., Gendler, S. J., Longenecker, B. M.> ;Mol Med Today. 1998 Sep
Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation.
Agrawal, B., Krantz, M. J., Parker, J., Longenecker, B. M.> ;Cancer Res. 1998 Sep 15
Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
Guan, H. H., Budzynski, W., Koganty, R. R., Krantz, M. J., Reddish, M. A., Rogers, J. A., Longenecker, B. M., Samuel, J.> ;Bioconjug Chem. 1998 Jul 01
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide.
Reddish, M., MacLean, G. D., Koganty, R. R., Kan-Mitchell, J., Jones, V., Mitchell, M. S., Longenecker, B. M.> ;Int J Cancer. 1998 Jun 10
Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa.
Ogata, S., Koganty, R., Reddish, M., Longenecker, B. M., Chen, A., Perez, C., Itzkowitz, S. H.> ;Glycoconj J. 1998 Jan
Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.
Samuel, J., Budzynski, W. A., Reddish, M. A., Ding, L., Zimmermann, G. L., Krantz, M. J., Koganty, R. R., Longenecker, B. M.> ;Int J Cancer. 1998 Jan 19
Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2.
Agrawal, B., Krantz, M. J., Reddish, M. A., Longenecker, B. M.> ;Nat Med. 1998 Jan
Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies.
Reddish, M. A., Suresh, M. R., Koganty, R. R., Fortier, S., Baronic, L., Berg, A., Longenecker, B. M.> ;Tumour Biol. 1998
Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.
Reddish, M. A., Jackson, L., Koganty, R. R., Qiu, D., Hong, W., Longenecker, B. M.> ;Glycoconj J. 1997 Aug
Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients.
MacLean, G. D., Reddish, M. A., Longenecker, B. M.> ;J Immunother. 1997 Jan
Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens.
O'Boyle, K. P., Markowitz, A. L., Khorshidi, M., Lalezari, P., Longenecker, B. M., Lloyd, K. O., Welt, S., Wright, K. E.> ;Hybridoma. 1996 Dec
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
Miles, D. W., Towlson, K. E., Graham, R., Reddish, M., Longenecker, B. M., Taylor-Papadimitriou, J., Rubens, R. D.> ;Br J Cancer. 1996 Oct
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
MacLean, G. D., Miles, D. W., Rubens, R. D., Reddish, M. A., Longenecker, B. M.> ;J Immunother Emphasis Tumor Immunol. 1996 Jul
CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors.
Agrawal, B., Reddish, M., Longenecker, B. M.> ;J Immunol. 1996 Oct 15
Join now to see all

Hospital Affiliations

SCL Health - St. Mary's Hospital and Medical CenterGrand Junction, Colorado